文献速递药物不良反应与药物警戒

大麻素相关急性胰腺炎:国际文献与个例安全性报告更新

Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports.
PubMed 文献 · Drug Saf · 2022-02-18

治疗性使用涉及13例,停药后多转归良好,再暴露或持续使用常见复发。横断面研究提示急性胰腺炎住院患者大麻使用呈上升趋势且院内死亡率较低。

要点

  • 大麻素使用(娱乐性或治疗性)可能是急性胰腺炎的潜在不良反应。
  • 再暴露或持续使用大麻素时急性胰腺炎复发频繁。
  • 急性胰腺炎住院患者中大麻使用呈上升趋势,但院内死亡率显著较低。

核心结论

  • 大麻素相关急性胰腺炎是潜在不良反应,常未被识别,可发生于娱乐性或治疗性使用。
  • 在虚弱患者中开发大麻素治疗用途时,需更好地评估不同产品的获益-风险比。

研究设计与样本

  • 研究向9个国家和国际药物警戒数据库索取大麻素暴露相关急性胰腺炎的个例安全性报告。
  • 系统检索PubMed、Web of Science和Google Scholar,纳入病例报告、观察性研究、临床试验或综述,检索更新至2021年1月1日。

主要发现

  • 病例以年轻男性为主(74%为男性,中位年龄28岁,四分位距[21-39]),多为高强度娱乐性使用大麻。
  • 13例为治疗性使用,涉及四氢大麻酚、大麻二酚和屈大麻酚。
  • 停药后转归常良好(除外3例死亡),再暴露或持续使用时常观察到复发。

临床怎么用

  • 临床应警惕大麻素使用(包括娱乐性和治疗性)患者发生急性胰腺炎的可能。
  • 对大麻素相关急性胰腺炎患者,应询问再暴露或持续使用情况以评估复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In addition to the growing interest of different cannabinoids for therapeutic purposes, the safety profile of these substances has changed, with the recent identification of new events such as acute pancreatitis. OBJECTIVE: The aim of this study was to characterize cannabinoid-related acute pancreatitis, based on the recent literature and the analysis of pharmacovigilance data available worldwide. METHODS: Nine national and international pharmacovigilance databases were requested for individual case safety reports of acute pancreatitis related to cannabinoid exposure. A systematic review was performed searching in PubMed®, Web of Science®, and Google Scholar® for any publication dealing with acute pancreatitis and cannabinoid exposure (cannabis, cannabinoid, cannabidiol, tetrahydrocannabinol, nabilone, dronabinol), to identify case reports, observational studies, clinical trials, or reviews. All queries were updated on 1 January, 2021. RESULTS: Twenty-two individual case safety reports were identified in the pharmacovigilance databases and 51 in the literature, corresponding to a predominantly young male population (74% of men, median age 28 interquartile range [21-39]) using recreational Cannabis sativa with high intensity. A therapeutic purpose was identified in 13 cases (including tetrahydrocannabinol, cannabidiol, and dronabinol). The outcome was often favorable after dechallenge (except three deaths), and frequent recurrences were observed in the case of rechallenge or sustained consumption. Eleven cross-sectional studies and one ecological study showed an increasing trend of cannabis use in in-patients with acute pancreatitis, with a significantly lower in-hospital mortality. CONCLUSIONS: This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use. It remains often unrecognized and can occur during recreational or therapeutic use. The development of the therapeutic use of cannabinoids in frail patients deserves a better investigation of the benefit-risk ratio of these different products.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Azam C, Buscail L, Culetto A, et al. Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports. Drug Saf. 2022. PMID: 35179705. doi:10.1007/s40264-022-01146-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。